Therapeutic Focus Treeway targets ALS, Alzheimer's and other neurodegenerative diseases, signaling opportunities for co development, licensing or exclusive collaboration around TW001 and future assets with pharma partners and CRO networks.

Global Partnership Track Past licensing and distribution partnerships in Europe, Asia and Australia and New Zealand (Ferrer Deutschland, Specialised Therapeutics) demonstrate a readiness to engage regional partners for development, registration and commercialization.

Clinical Milestones Upcoming and recently disclosed clinical milestones, including acceptance of TW001 ASURE results for CTAD 2025, create openings for data driven partnerships, co promotion discussions, and research collaborations with academic and biotech ecosystems.

Growth Readiness As a small clinical stage company with modest revenues, Treeway could benefit from scalable services such as CRO staffing, regulatory affairs, and manufacturing partnerships to accelerate trials and prepare for commercialization.

Patient Centricity A patient driven branding and mission statement positions Treeway for partnerships with patient advocacy groups, clinical trial networks, and strategic investors looking to back neurodegenerative therapies and first in class approaches.